These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19571029)

  • 21. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.
    Cuenca-Estrella M; Gomez-Lopez A; Cuesta I; Zaragoza O; Mellado E; Rodriguez-Tudela JL;
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1794-7. PubMed ID: 21282420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
    Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
    Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
    Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2008 Feb; 46(2):551-9. PubMed ID: 18094129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential fungicidal effect of voriconazole against Candida spp.
    Rubio MC; de Ocáriz IR; Gil J; Benito R; Rezusta A
    Int J Antimicrob Agents; 2005 Mar; 25(3):264-7. PubMed ID: 15737524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
    Chryssanthou E; Cuenca-Estrella M
    J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
    Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
    J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.
    Espinel-Ingroff A; Canton E; Peman J; Martín-Mazuelo E
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1347-50. PubMed ID: 20028814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
    Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activity of voriconazole against yeasts isolated from blood culture determined by two methods].
    Cantón E; Pemán J; Bosch M; Viudes A; Gobernado M
    Rev Esp Quimioter; 2005 Dec; 18(4):308-12. PubMed ID: 16446790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Huynh H; Hollis RJ
    J Clin Microbiol; 2002 May; 40(5):1694-7. PubMed ID: 11980944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.
    Lozano-Chiu M; Arikan S; Paetznick VL; Anaissie EJ; Rex JH
    J Clin Microbiol; 1999 Sep; 37(9):2755-9. PubMed ID: 10449447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
    Pfaller MA; Espinel-Ingroff A; Jones RN
    J Clin Microbiol; 2004 Oct; 42(10):4577-80. PubMed ID: 15472311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.